| Literature DB >> 33262066 |
Ernesto Leon1, Raghuveer Ranganathan2, Barbara Savoldo3.
Abstract
Cellular therapies have shown increasing promise as a cancer treatment. Encouraging results against hematologic malignancies are paving the way to move into solid tumors. In this review, we will focus on T-cell therapies starting from tumor infiltrating lymphocytes (TILs) to optimized T-cell receptor-modified (TCR) cells and chimeric antigen receptor-modified T cells (CAR-Ts). We will discuss the positive preclinical and clinical findings of these approaches, along with some of the persisting barriers that need to be overcome to improve outcomes.Entities:
Keywords: Adoptive cell therapy; CAR-T cells; Cytolytic T cells (CTLs); Hematologic malignancies; T-cell receptor-modified (TCR) cells; Tumor infiltrating T cells (TILs)
Year: 2020 PMID: 33262066 DOI: 10.1016/j.smim.2020.101437
Source DB: PubMed Journal: Semin Immunol ISSN: 1044-5323 Impact factor: 11.130